Pharmacologic effects of paclitaxel in human bladder tumors

1997 ◽  
Vol 41 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Jessie L.-S. Au ◽  
John Kalns ◽  
Yuebo Gan ◽  
M. Guillaume Wientjes
Keyword(s):  
Oncogene ◽  
2003 ◽  
Vol 22 (22) ◽  
pp. 3361-3370 ◽  
Author(s):  
Weicheng Wu ◽  
Xiaodong Shu ◽  
Harut Hovsepyan ◽  
Raymond D Mosteller ◽  
Daniel Broek

1988 ◽  
Vol 43 (4) ◽  
pp. 335-342 ◽  
Author(s):  
Pamela J. Russell ◽  
Jeanette Philips ◽  
William Allan ◽  
David A. Hume

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4591-4591
Author(s):  
Phillip Lee Palmbos ◽  
Lidong Wang ◽  
Huibin Yang ◽  
Taylor Detzler ◽  
Gina Ney ◽  
...  

4591 Background: Bladder cancer is a common and deadly disease, but the molecular events leading to its initiation and progression are incompletely understood. We recently identified Ataxia-Telangiectasia Group D Associated (ATDC) as a novel oncogene which drives tumor proliferation and invasion in pancreatic carcinoma (Cancer Cell, 2009). In this study, we describe the role of ATDC as an oncogene in bladder cancer. Methods: To further determine the oncogenic role of ATDC, we generated ATDC transgenic (tg) mice in which ATDC expression was driven by a CMV promoter and characterized the resulting tumors. Results: Interestingly, the dominant phenotype in these mice was the development of both non-invasive and invasive urothelial carcinomas (9% and 20% respectively, average age of onset 10-12 months of age). Histologically, these tumors were indistinguishable from human urothelial carcinomas. Gene expression profiling of invasive tumors derived from ATDC tg mice demonstrated a marked overlap with gene signatures of human invasive bladder cancers. ATDC was the 11th most highly up-regulated gene in bladder cancers represented in the Oncomine gene expression database. Analysis of a human bladder cancer tissue microarray (311 samples) by IHC showed elevated expression in 70% (173/252) of muscle-invasive carcinomas, 22% (5/23) of papillary tumors and little or no expression in normal bladder urothelium. ATDC tg mouse bladder tumors demonstrated loss of p53 signaling and down-regulation of PTEN expression, which correlated with ATDC induced methylation of the PTEN promoter by DNMT3A. Furthermore, ATDC knock-down in invasive cancer cell lines resulted in decreased proliferation, invasion and reactivation of p53-mediated signaling and PTEN expression. Conclusions: ATDC is a novel oncogene that is highly expressed in human bladder cancers and is sufficient to drive the development of invasive bladder tumors in tg mice. The mechanism by which ATDC drives bladder cancer formation involves alterations in p53 and PTEN pathways known to be important in bladder tumorigenesis.


1995 ◽  
Vol 87 (20) ◽  
pp. 1524-1529 ◽  
Author(s):  
I. Orlow ◽  
L. Lacombe ◽  
G. J. Hannon ◽  
M. Serrano ◽  
I. Pellicer ◽  
...  
Keyword(s):  

1992 ◽  
Vol 61 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Eva Agurell ◽  
Ronggui Li ◽  
Ulf Rannug ◽  
Ulf Norming ◽  
Bernhard Tribukait ◽  
...  

2020 ◽  
Author(s):  
Victoria Vitti Gambim ◽  
Renee Laufer-Amorim ◽  
Ricardo Fonseca Alves ◽  
Valeria Grieco ◽  
Carlos Eduardo Fonseca-Alves

AbstractCanine and human bladder cancer present several similar anatomical, morphological and molecular characteristics and dogs can be considered a model for human bladder cancer. However, the veterinary literature lacks information regarding cross validation analysis between human and canine large-scale data. Therefore, this research aimed to perform a meta-analysis of the previous canine literature on bladder cancer, identifying genes and protein previously evaluated in these studies. Besides that, we also performed a cross validation of the canine transcriptome data and the human data from The Cancer Genome Atlas (TCGA) to identify potential markers for both species. It was performed a meta-analysis using the following indexing terms “bladder” AND “carcinoma” AND “dog” in different international databases and 385 manuscripts were identified in our initial search. Then, several inclusion criteria were applied and only 25 studies met these criteria. Among these studies, five presented transcriptome data and 20 evaluated only isolated genes or proteins.Regarding the studies involving isolated protein analysis, HER-2 protein was the most studied (3/20), followed by TAG-72 (2/20), COX-2 (2/2), Survivin (2/2) and CK7 (2/2). Regarding the cross-validation analysis of human and canine transcriptome data, we identified 35 deregulated genes, including ERBB2, TP53, EGFR and E2F2. Our results demonstrated that the previous canine literature on bladder cancer was focused on the evaluation of isolated markers with no association with patient’s survival. Besides that, the lack of information regarding tumor muscle-invasion can be considered an important limitation when comparing human and canine bladder tumors. Our in-silico analysis involving canine and human transcriptome data provided several genes with potential to be markers for both human and canine bladder tumors and these genes should be considered for future studies on canine bladder cancer.


Sign in / Sign up

Export Citation Format

Share Document